MedTrace Logo

Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder

NCT00829881 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2013-09-26

No results posted yet for this study

Summary

This study will determine whether the drug betahistine increases focus and causes side effects in people with attention deficit hyperactivity disorder.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

DRUG

Betahistine Hydrochloride

A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks

DRUG

Placebo Capsule

A single placebo capsule

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • P2D, Inc.

    lead INDUSTRY

Principal Investigators

  • Charles H. Pierce, MD, PhD · P2D, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00829881 on ClinicalTrials.gov